ArticleAdvanced healthcare materials2026
Engineering of Glioblastoma-Derived Biomimetic Vesicles and Their Structural and Molecular Features.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Biomimetic nanosystems and vesicles have arisen as a novel approach to design vesicular transport systems with diverse therapeutic potential. The 'biomimetic' strategy involves the integration of cell membrane components into lipid bilayers, conferring them with biological properties originating from the cell of origin. Until now, most studies have primarily focused on the evaluation of the biological activity and function of different biomimetic nanosystems with limited exploration of the engineering parameters selected and little characterization of their features at the molecular level. This study aimed to address this knowledge gap by describing a preparation method for biomimetic lipid vesicles using traditional liposome fabrication principles and cellular components exclusively derived from glioblastoma (GL261) cell membrane proteins. Critical engineering parameters were studied, such as bilayer lipid and cholesterol content, the degree of surface PEGylation and some processing aspects like purification and quantification. Following fabrication, the GL261-derived vesicles underwent purification using size exclusion chromatography to separate unbound proteins from the vesicles. Subsequently, the GL261-derived vesicles were characterized by cryo-EM and differential scanning calorimetry (DSC) to assess their morphological and thermal properties, respectively. Both cholesterol and PEGylated lipid content played an important role on the structural and colloidal features of the biomimetic vesicles (BV). Mass spectroscopy (LC-MS/MS) revealed the proteomic signature of the fabricated vesicles at the molecular level. Collectively, these findings advance the rational engineering of BV and offer an in-depth proteomic framework that reveals their molecular identity and functional potential. By connecting the design principles of fabrication with the molecular features of the vesicles, this study paves the way for next-generation biomimetic platforms for cancer chemotherapy, immunomodulation and cancer vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.